Basal Cell Carcinoma Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Surgery, Medications, Others), By End User (Hospitals, Specialty Clinics, Others) By Region, And Segment Forecasts, 2023 - 2030

Market Size & Trends

The global basal cell carcinoma treatment market size was valued at USD 6.80 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8.03% from 2023 to 2030. This is attributed to the rising incidence of basal cell carcinoma, growing advancements in the treatment process, and increasing number of research & development in the oncology fields. Moreover, the growing awareness among individuals and the importance of early detection is anticipated to further fuel the market growth from 2023 to 2030.

According to the article published in April 2022 by the American Academy of Dermatology Association, skin cancer holds the highest prevalence among all types of cancer in the U.S. population. Around one in five citizens in America is expected to experience skin cancer during their lifetimes. In the U.S., approximately 9,500 individuals are diagnosed with skin cancer each day. In addition, non-melanoma skin cancer (NMSC), comprising squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), affects over 3 million Americans every year. 

Furthermore, increasing research & development activities in the field of oncology, including basal cell carcinoma treatment, are anticipated to drive the market forward. For instance, research presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting in October 2022 by Pulse Biosciences showcased the effectiveness of the CellFX procedure in removing low-risk superficial and nodular basal cell carcinoma lesions by means of Nano-Pulse Stimulation (NPS) technology. These advancements, combined with the rising prevalence of cancer, are expected to stimulate the market growth.

Treatment Type Insights

The surgery segment held the largest market share in 2022. This is attributed to advancements in surgical techniques, minimally invasive procedures, and a heightened awareness of skin cancer, leading to early diagnosis and treatment. Furthermore, surgeries are patients’ primary choice due to their high success rates and proven efficacy, thus stimulating a growing demand for effective treatment. The medications segment is anticipated to grow at the fastest CAGR from 2023 to 2030 owing to the growing advancements in personalized medicine and awareness on early detection.

End-use Insights

On the basis of end-use, the market is segmented into hospitals, specialty clinics, and others. The hospital segment dominated the market in 2022. Hospitals are centers for cancer care, diagnosis, and treatment. They help as acute centers for patient management, facilitating collaborative efforts among healthcare professionals and rising advancements in research and development. The combined efforts within hospitals are anticipated to enhance cancer care, with a focus on improving patient outcomes, early detection, and personalized treatment plans.

Regional Insights

North America dominated the market in 2022 owing to the increasing number of skin diseases in the region. According to the Canadian Dermatology Association, in 2020, approximately 8,000 individuals in Canada are currently dealing with melanoma, with about 4,400 being men and 3,600 being women. Melanoma has now become the seventh most prevalent cancer in the country, presenting a remarkable increase in incidence rates among Canadians. The same source highlights that non-melanoma skin cancer is the most frequently occurring type. Within the non-melanoma category, basal cell carcinoma (BCC) accounts for 75% to 80% of cases, while squamous cell carcinoma (SCC) represents around 20%.

Furthermore, the growing number of clinical trials related to oncology is anticipated to boost market growth. For instance, in November 2021, The Center for Biomedical Research, Inc. concluded a randomized comparative study comparing the effectiveness of a 30% solution of ascorbic acid in 95% dimethylsulfoxide applied topically twice daily for eight weeks compared to 5% imiquimod cream in treating biopsy-proven basal cell carcinomas in adult patients who are otherwise in good health.

Key Companies & Market Share Insights

Key players operating in the market are Merck & Co., Inc., Allergan Inc., Bausch Health Companies, Perrigo Company Plc., F. Hoffmann-La Roche Ltd., Sun Pharmaceuticals Ltd., Strides Arcolab Ltd., and Mylan N.V. among others. The market participants are constantly working towards new product development, R&D activities, and other strategic alliances to gain new market avenues.

The following are some instances of strategic initiatives:

• In June 2021, Regeneron Pharmaceuticals, Inc. and Sanofi together developed Libtayo, a PD-1 inhibitor. The European Commission (EC) granted authorization for the usage of Libtayo in treating adults afflicted with locally advanced or metastatic basal cell carcinoma (BCC) who have experienced progression or intolerance to a hedgehog pathway inhibitor (HHI).

• In February 2021, Libtayo, a PD-1 inhibitor by Sanofi and the pioneering immunotherapy for patients facing advanced basal cell carcinoma, has been granted approval by the U.S. FDA.